Nestle Invests $43 Million in Maker of Disease-Battling ProteinsBy
CEO of Health Science unit Behar also joins startup's board
Pronutria targets diseases caused by amino acid imbalances
Nestle SA, the world’s biggest food company, invested $43 million in Pronutria Biosciences, a U.S. developer of proteins that target neurological, muscle and liver diseases, its latest investment in a health startup.
Pronutria has a product in clinical testing to treat muscle-wasting diseases caused by imbalances in amino acids, Nestle said Tuesday in a statement. Greg Behar, chief executive officer of the Swiss firm’s Health Science unit, will join the board of the Cambridge, Massachusetts-based startup.
The U.S. company is engaged in “paradigm-changing science” to address unmet medical needs, Behar said in the statement.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.
- A L'Oreal Heiress Is Now the World's Richest Woman
- Ivanka Trump Faces Courtroom Showdown Over $785 Sandals
- How Electric Cars Can Create the Biggest Disruption Since the iPhone
- Uber Losing Battle in London After Regulator Revokes License
- A Storm's Never Destroyed a Grid Like Maria Ruined Puerto Rico's